<DOC>
	<DOCNO>NCT00147394</DOCNO>
	<brief_summary>The purpose research study pharmacokinetics risperidone group pediatric patient Pervasive Developmental Disorder ( PDD ) . The study determine much risperidone breakdown product , 9-hydroxy-risperidone , blood follow patient 's usual daily dose . The study design look fast child absorb , breakdown , eliminate risperidone .</brief_summary>
	<brief_title>Risperidone Pharmacokinetics Children With Pervasive Developmental Disorder ( PDD )</brief_title>
	<detailed_description>Pervasive Developmental Disorders category disorder include autism related condition . While disorder rare , represent significant public health problem extremely debilitate lack efficacious therapy . Neuroleptic use PDD high population appear increase risk serious sequela include tardive dyskinesia . Newer atypical neuroleptic include risperidone use 87 % case dose , safety efficacy undetermined vulnerable population . This study consist total 3 visit , initial screen visit consent , medical history , demographic vitals record . Two additional visit blood sample occur . The second visit great 30 day screen visit 3rd visit one month Visit 2 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male female patient age 5 less 17 year . Patients meet DSMIV criterion PDDNOS initiate clinical treatment currently clinically treat risperidone . Patients autistic disorder PDDNOS currently risperidone participant one multisite RUPP protocols . Children take psychotropic medication interact target CYP 450 isoenzyme activity eligible pharmacokinetic study ( i.e . CYP2D6 CYP3A4 ; decide PI ) Patients know renal hepatic dysfunction ( e.g . serum creatinine &gt; 1.5 normal upper limit , transaminases bilirubin &gt; 2 time normal upper limit ) Failure parent/legal guardian give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Risperidone</keyword>
	<keyword>Autism</keyword>
	<keyword>PDD</keyword>
	<keyword>Pervasive Developmental Disorder</keyword>
</DOC>